| Schedule of net revenues by product |
The following tables detail AbbVie's worldwide net revenues: | | | | | | | | | | | | | | | | | | | | | | years ended December 31 (in millions) | 2020 | | 2019 | | 2018 | | Immunology | | | | | | | Humira | United States | $ | 16,112 | | | $ | 14,864 | | | $ | 13,685 | | | International | 3,720 | | | 4,305 | | | 6,251 | | | Total | $ | 19,832 | | | $ | 19,169 | | | $ | 19,936 | | | Skyrizi | United States | $ | 1,385 | | | $ | 311 | | | $ | — | | | International | 205 | | | 44 | | | — | | | Total | $ | 1,590 | | | $ | 355 | | | $ | — | | | Rinvoq | United States | $ | 653 | | | $ | 47 | | | $ | — | | | International | 78 | | | — | | | — | | | Total | $ | 731 | | | $ | 47 | | | $ | — | | | Hematologic Oncology | | | | | | | Imbruvica | United States | $ | 4,305 | | | $ | 3,830 | | | $ | 2,968 | | | Collaboration revenues | 1,009 | | | 844 | | | 622 | | | Total | $ | 5,314 | | | $ | 4,674 | | | $ | 3,590 | | | Venclexta | United States | $ | 804 | | | $ | 521 | | | $ | 247 | | | International | 533 | | | 271 | | | 97 | | | Total | $ | 1,337 | | | $ | 792 | | | $ | 344 | | | Aesthetics | | | | | | Botox Cosmetic (a) | United States | $ | 687 | | | $ | — | | | $ | — | | | International | 425 | | | — | | | — | | | Total | $ | 1,112 | | | $ | — | | | $ | — | | Juvederm Collection (a) | United States | $ | 318 | | | $ | — | | | $ | — | | | International | 400 | | | — | | | — | | | Total | $ | 718 | | | $ | — | | | $ | — | | Other Aesthetics (a) | United States | $ | 666 | | | $ | — | | | $ | — | | | International | 94 | | | — | | | — | | | Total | $ | 760 | | | $ | — | | | $ | — | | | Neuroscience | | | | | | Botox Therapeutic (a) | United States | $ | 1,155 | | | $ | — | | | $ | — | | | International | 232 | | | — | | | — | | | Total | $ | 1,387 | | | $ | — | | | $ | — | | Vraylar (a) | United States | $ | 951 | | | $ | — | | | $ | — | | | | | | | | | | | | | | | | | Duodopa | United States | $ | 103 | | | $ | 97 | | | $ | 80 | | | International | 391 | | | 364 | | | 350 | | | Total | $ | 494 | | | $ | 461 | | | $ | 430 | | Ubrelvy (a) | United States | $ | 125 | | | $ | — | | | $ | — | | | | | | | | | | | | | | | | Other Neuroscience (a) | United States | $ | 528 | | | $ | — | | | $ | — | | | International | 11 | | | — | | | — | | | Total | $ | 539 | | | $ | — | | | $ | — | |
| | | | | | | | | | | | | | | | | | | | | | years ended December 31 (in millions) | 2020 | | 2019 | | 2018 | | Eye Care | | | | | | Lumigan/Ganfort (a) | United States | $ | 165 | | | $ | — | | | $ | — | | | International | 213 | | | — | | | — | | | Total | $ | 378 | | | $ | — | | | $ | — | | Alphagan/Combigan (a) | United States | $ | 223 | | | $ | — | | | $ | — | | | International | 103 | | | — | | | — | | | Total | $ | 326 | | | $ | — | | | $ | — | | Restasis (a) | United States | $ | 755 | | | $ | — | | | $ | — | | | International | 32 | | | — | | | — | | | Total | $ | 787 | | | $ | — | | | $ | — | | Other Eye Care (a) | United States | $ | 305 | | | $ | — | | | $ | — | | | International | 388 | | | — | | | — | | | Total | $ | 693 | | | $ | — | | | $ | — | | | Women's Health | | | | | | Lo Loestrin (a) | United States | $ | 346 | | | $ | — | | | $ | — | | | International | 10 | | | — | | | — | | | Total | $ | 356 | | | $ | — | | | $ | — | | | Orilissa/Oriahnn | United States | $ | 121 | | | $ | 91 | | | $ | 11 | | | International | 4 | | | 2 | | | — | | | Total | $ | 125 | | | $ | 93 | | | $ | 11 | | Other Women's Health (a) | United States | $ | 181 | | | $ | — | | | $ | — | | | International | 11 | | | — | | | — | | | Total | $ | 192 | | | $ | — | | | $ | — | | | Other Key Products | | | | | | | Mavyret | United States | $ | 785 | | | $ | 1,473 | | | $ | 1,614 | | | International | 1,045 | | | 1,420 | | | 1,824 | | | Total | $ | 1,830 | | | $ | 2,893 | | | $ | 3,438 | | | Creon | United States | $ | 1,114 | | | $ | 1,041 | | | $ | 928 | | | Lupron | United States | $ | 600 | | | $ | 720 | | | $ | 726 | | | International | 152 | | | 167 | | | 166 | | | Total | $ | 752 | | | $ | 887 | | | $ | 892 | | Linzess/Constella (a) | United States | $ | 649 | | | $ | — | | | $ | — | | | International | 18 | | | — | | | — | | | Total | $ | 667 | | | $ | — | | | $ | — | | | Synthroid | United States | $ | 771 | | | $ | 786 | | | $ | 776 | | | All other | | $ | 2,923 | | | $ | 2,068 | | | $ | 2,408 | | | Total net revenues | $ | 45,804 | | | $ | 33,266 | | | $ | 32,753 | |
|
| Schedule of net revenues to external customers by geographic area |
Net revenues to external customers by geographic area, based on product shipment destination, were as follows: | | | | | | | | | | | | | | | | | | | years ended December 31 (in millions) | 2020 | | 2019 | | 2018 | | United States | $ | 34,879 | | | $ | 23,907 | | | $ | 21,524 | | | Japan | 1,198 | | | 1,211 | | | 1,591 | | | Canada | 1,159 | | | 813 | | | 730 | | | Germany | 1,049 | | | 909 | | | 1,292 | | | France | 797 | | | 695 | | | 783 | | | Australia | 527 | | | 395 | | | 350 | | | United Kingdom | 509 | | | 372 | | | 855 | | | China | 471 | | | 195 | | | 152 | | | Spain | 453 | | | 472 | | | 611 | | | Brazil | 406 | | | 359 | | | 350 | | | Italy | 379 | | | 372 | | | 652 | | | All other countries | 3,977 | | | 3,566 | | | 3,863 | | | Total net revenues | $ | 45,804 | | | $ | 33,266 | | | $ | 32,753 | |
|
| Schedule of long-lived assets by geographic area |
Long-lived assets, primarily net property and equipment, by geographic area were as follows: | | | | | | | | | | | | | as of December 31 (in millions) | 2020 | | 2019 | | United States and Puerto Rico | $ | 3,354 | | | $ | 2,026 | | | Europe | 1,534 | | | 646 | | | All other | 360 | | | 290 | | | Total long-lived assets | $ | 5,248 | | | $ | 2,962 | |
|